Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

Newly engineered lignin nanocarrier for curcumin delivery to tackle inflammation and limited synovial drug residence in osteoarthritis

Objetivo

Osteoarthritis (OA) characterized by damage to the articular cartilage and skeletal overgrowth around the joints. OA affecting approximately 8.75 million people in the UK. In the UK, France, and Spain, OA incurs significant annual direct and indirect costs, estimated at up to €7.2 billion and €4.6 billion. Clinical approaches to treating OA include non-pharmacologic methods (lifestyle changes), pharmacologic management (common medications), and surgical interventions. Pharmacologic treatments often have serious side effects over time, including stomach or heart problems. Therefore, it is needed a safe and effective substance with fewer side effects. Curcumin lead to better pain management, improved joint function, diminish inflammation, and a reduced reliance on conventional medications. Intra-articular (IA) injections of curcumin is anti side effects, common, but a major limitation is the short duration that these curcumin remain in the synovial joint, leading to require repeated injections. In this project, I aim to develop an innovative biodegradable nanocarrier, loaded with curcumin, using Gemini surfactants as a smart drug delivery system with slow-release properties specifically designed to address inflammation in osteoarthritis (OA). Unlike currently available commercial products, my nanocarrier is designed to prevent rapid drug clearance from the joints, enhancing drug release at least 100-fold slower than existing options. The key features of my nanocarriers include the creation of spherical nanoparticles with optimized charge to enhance lubrication in the joints, as well as achieving long-term dispersion stability through the use of Gemini surfactants. This formulation with lignin nanoparticles offer high biocompatibility, low inflammatory effects, and minimal systemic side effects. It overcomes the significant limitations of current OA treatments while also reducing environmental impact by using fewer organic solvents and more biodegradable materials.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) HORIZON-MSCA-2025-PF

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

UNIVERSITY OF LEEDS
Aportación neta de la UEn
€ 276 187,92
Dirección
WOODHOUSE LANE
LS2 9JT Leeds
Reino Unido
Región
Yorkshire and the Humber West Yorkshire Leeds
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
Sin datos